ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2965

Might Troponin be a Marker for Subclinical Scleroderma Heart Involvement (SHI)?

Chiara Stagnaro1, Anna d'Ascanio1, Alice Parma2, Umberto Conti3, Michele Emdin4, Alessandra Della Rossa1 and Marta Mosca1, 1Internal Medicine, University of Pisa, Pisa, Italy, 2University of Pisa, Pisa, Italy, 3Cardiotoracico, Cardiologia 2, Pisa, Italy, 4Fondazione Toscana Gabriele Monasterio, UOC Cardiologia e Medicina Cardiovascolare, Pisa, Italy

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, heart disease and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease with pronounced alterations of the microvascular system, frequent cellular and humoral immunity abnormalities and fibroblast dysfunction. All these events result in an overproduction of collagen with possible involvement of skin and internal organs. Cardiac involvement is common in SSc; it is often asymptomatic and insidious, but almost invariably associated with ominous outcome. For this reason it is essential to identify markers useful to early recognize any sort of SHI. The aim of this study was to investigate if  high sensitivity troponin (HSTn) could be helpful  to identify subclinical SHI.

Methods: for this purpose we analyzed data of 65 consecutive SSc patients (M:F = 4:61; mean age 59,4 years, range 24-95 years; mean disease duration 10,3 years; 33 with lcSSc, 32 with dcSSc) followed at our unit. Among all our SSc patients admitted in the last two years, we selected only those who underwent the following laboratory and instrumental investigations: HSTn,  electrocardiogram  and an echocardiogram within six months of HSTn test. Most of patients performed also N-terminal segment of proBNP (NT-proBNP) test and three patients underwent cardiac magnetic resonance imaging (cMRI). We excluded from our study patients with overt pulmonary arterial hypertension since it could alter cardiac markers. For six of the selected patients we collected data in more than one occasion. Furthermore we defined as SHI the presence of one or more of these conditions, in the absence of any other causes: diastolic dysfunction (at least grade II or grade I if patient is younger than 50 years or in presence of other manifestations of SHI), pericardial effusion, conduction abnormalities (bundle branch block or atrioventricular block) or arrhythmias, edema and/or T2 weighted non ischemic pattern showed by cMRI. Correlation between laboratory data and instrumental measurements were performed by non parametric tests for continuous variables and contingency tables for categorical variables (Stat-View, SAS). Fisher exact test was applied when indicated.

Results: among the analyzed patients 13 showed SHI and 23 and 29 had respectively high levels of HSTn and of NT-proBNP. SHI seems to be correlated only with high levels of HSTn (p 0,02) with a significant difference between the HSTn values of patients with or without SHI (59 versus 13ng/ml; p 0,0097). Moreover we observed a strictly correlation between NT-proBNP and HSTn: among patients with abnormal NT-proBNP, 18 had also out of range HSTn (spearman rank correlation 0,5; p <0.0001).

Conclusion: Our data shows a close relationship between HSTn and NT-proBNP in SSc patients with SHI. However, if we consider these 2 serological parameters independently, we observe that HSTn might be a marker of SHI while NT-proBNP seems to be a less specific index of heart dysfunction. Since SHI is often subclinical, but anyway associated with a significantly increased morbidity and mortality, a serological marker would be very useful not only to early diagnose SHI but also to select patients who need additional investigations such as cMRI. However further studies are necessary to confirm these preliminary results.


Disclosure: C. Stagnaro, None; A. d'Ascanio, None; A. Parma, None; U. Conti, None; M. Emdin, None; A. Della Rossa, None; M. Mosca, None.

To cite this abstract in AMA style:

Stagnaro C, d'Ascanio A, Parma A, Conti U, Emdin M, Della Rossa A, Mosca M. Might Troponin be a Marker for Subclinical Scleroderma Heart Involvement (SHI)? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/might-troponin-be-a-marker-for-subclinical-scleroderma-heart-involvement-shi/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/might-troponin-be-a-marker-for-subclinical-scleroderma-heart-involvement-shi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology